Antares Pharma Overview

  • Year Founded
  • 1979

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 203

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.05B

Antares Pharma General Information

Description

Developer of pharmaceutical products intended to serve the rheumatology, urology, endocrinology, and neurology sectors. The company offers testosterone enanthate injections, testosterone undecanoate capsules, epinephrine injections, and proprietary auto injector devices, enabling patients to receive medications through advanced delivery formats that improve safety and efficacy. and treatment adherence.

Contact Information

Formerly Known As
Medi Ject
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Princeton South
  • Suite 300
  • Ewing, NJ 08628
  • United States
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Corporate Office
  • 100 Princeton South
  • Suite 300
  • Ewing, NJ 08628
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antares Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
20. Merger/Acquisition 24-May-2022 $1.05B Completed Profitable
19. Debt Refinancing 12-Nov-2021 Completed Profitable
18. PIPE 03-Oct-2012 Completed Generating Revenue
17. Secondary Transaction - Open Market 01-Sep-2007 Completed Generating Revenue
16. PIPE 23-Jun-2007 Completed Generating Revenue
15. Debt - General 28-Feb-2007 Completed Generating Revenue
14. PIPE 23-Feb-2004 Completed Generating Revenue
13. PIPE 08-Jul-2003 Completed Generating Revenue
12. PIPE 15-Jul-2002 $700K $28.7M Completed Generating Revenue
11. PIPE 06-Mar-2001 $10M $28M Completed Generating Revenue
To view Antares Pharma’s complete valuation and funding history, request access »

Antares Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical products intended to serve the rheumatology, urology, endocrinology, and neurology sectors.
Drug Delivery
Ewing, NJ
203 As of 2021

Cincinnati, OH
 

Lyon, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antares Pharma Competitors (12)

One of Antares Pharma’s 12 competitors is Enable Injections, a Venture Capital-Backed company based in Cincinnati, OH.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enable Injections Venture Capital-Backed Cincinnati, OH
Nemera Private Equity-Backed Lyon, France
QuVa Pharma Private Equity-Backed Sugar Land, TX
CNBX Pharmaceuticals Corporation Bethesda, MD
Lipocine Corporation Salt Lake City, UT
You’re viewing 5 of 12 competitors. Get the full list »

Antares Pharma Patents

Antares Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4496575-A1 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol Pending 21-Mar-2022
EP-4496575-A4 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol Pending 21-Mar-2022
US-12102643-B2 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol Active 21-Mar-2022
US-12521404-B2 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol Active 21-Mar-2022
US-20230302016-A1 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol Active 21-Mar-2022 A61K31/573
To view Antares Pharma’s complete patent history, request access »

Antares Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antares Pharma Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amarin Corporation Corporation Minority
Aventic Partners PE/Buyout Minority
Becton, Dickinson and Company Corporation Minority
Calvert Research and Management Impact Investing Minority
Cherry Tree & Associates Investment Bank Minority
You’re viewing 5 of 14 investors. Get the full list »

Antares Pharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.11 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Antares Pharma’s complete esg history, request access »

Antares Pharma FAQs

  • When was Antares Pharma founded?

    Antares Pharma was founded in 1979.

  • Where is Antares Pharma headquartered?

    Antares Pharma is headquartered in Ewing, NJ.

  • What is the size of Antares Pharma?

    Antares Pharma has 203 total employees.

  • What industry is Antares Pharma in?

    Antares Pharma’s primary industry is Drug Delivery.

  • Is Antares Pharma a private or public company?

    Antares Pharma is a Private company.

  • What is the current valuation of Antares Pharma?

    The current valuation of Antares Pharma is .

  • What is Antares Pharma’s current revenue?

    The current revenue for Antares Pharma is .

  • How much funding has Antares Pharma raised over time?

    Antares Pharma has raised $158M.

  • Who are Antares Pharma’s investors?

    Amarin Corporation, Aventic Partners, Becton, Dickinson and Company, Calvert Research and Management, and Cherry Tree & Associates are 5 of 14 investors who have invested in Antares Pharma.

  • Who are Antares Pharma’s competitors?

    Enable Injections, Nemera, QuVa Pharma, CNBX Pharmaceuticals, and Lipocine are some of the 12 competitors of Antares Pharma.

  • When was Antares Pharma acquired?

    Antares Pharma was acquired on 24-May-2022.

  • Who acquired Antares Pharma?

    Antares Pharma was acquired by Halozyme Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process